Evidence Supporting the Use of MRI as a Surrogate for Clinical Endpoints in Randomized Controlled Trials for Pediatric Multiple Sclerosis (P1.342)

Conclusions:Using longitudinal analysis we found significant effects of treatment on risk of relapse and Gd lesion rate, and a statistically significant relationship between the two. These findings suggest that Gd count may serve as appropriate outcome measure in pedMS clinical trials-particularly in trials of therapeutic agents known to reduce both clinical attacks and Gd counts in adult MS.Disclosure: Dr. Brown has received personal compensation for activities with NeuroRx Research as a consultant. Dr. O'Mahony has nothing to disclose. Dr. Yeh has nothing to disclose. Dr. Marrie has received research support from Canadian Institutes of Health Research, Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, Rx & D Health Research Foundation, Research Manitoba, Crohn's and Colitis Canada and Sanofi-Aventis. Dr. Bar-Or has received personal compensation for activities with Bayer, Bayhill Therapeutics, Berlex, Biogen Idec, BioMS, Diogenix, and Eli Lilly for consulting, serving on scientific advisory boards and/or as a speaker. Dr. Banwell has received personal compensation for activities with Novartis. Dr. Banwell has received personal compensation in an editorial capacity for Multiple Sclerosis and Related Disorders. Dr. Arnold has received personal compensation for activities with Coronado Biosciences, Consortium of Multiple Sclerosis Centers, Eli Lilly, EMD Serono, Genentech, Genzyme, GlaxoSmithKline, MS Forum, NeuroRx Research, Novartis, Opexa Therap...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Brown, R., OMahony, J., Yeh, E. A., Marrie, R.-A., Bar-Or, A., Banwell, B., Arnold, D., On behalf of the Canadian Pediatric Demyelinating Disease Network Tags: Pediatric Multiple Sclerosis Source Type: research